癃清片联合化学药治疗III型前列腺炎有效性及安全性的 Meta分析

目的 评价癃清片联合化学药治疗III型前列腺炎［即慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）］的疗效及安全性。方法 检索PubMed、Embase、Medline、Web of Science、Cochrane Library、中国学术期刊全文数据库（CNKI）、万方数据知识服务平台（Wanfang Data）、维普中文科技期刊数据库（VIP）、中国生物医学文献服务系统（SinoMed）等数据库自建库至2022年1月关于癃清片治疗CP/CPPS的临床随机对照试验（RCT），根据纳排标准筛选文献，并采用Revman 5.4软件进行Meta分析。结果 共纳入8项RCTs，共计1 000例患者，其中试验组503例、对照组497例。Meta分析结果显示治疗后试验组美国国立卫生院慢性前列腺炎症状评分症状总分［MD=?2.65，95% CI（?3.28，?2.03），P＜0.000 01］、疼痛症状评分［MD=?1.44，95% CI（?1.95，?0.92），P＜0.000 01］、生活质量评分［MD=?0.50，95% CI（?0.93，?0.06），P=0.03］均低于对照组；排尿症状评分与对照组比较差异不显著［MD=?0.17，95% CI（?0.85，0.50），P=0.61］，敏感性分析显示对照组干预措施仅应用1种化学药，则差异具有统计学意义［MD=?0.75，95% CI（?1.43，?0.07），P=0.03］；前列腺按摩液中白细胞计数低于对照组［MD=?4.33，95% CI（?6.59，?2.08），P=0.002］；不良反应发生率与对照组比较差异不显著［RR=1.00，95% CI（0.46，2.19），P=0.99］。结论 癃清片能显著改善CP/CPPS患者症状，降低前列腺按摩液中白细胞数量，且不会显著增加不良反应的发生。

Meta-analysis of efficacy and safety of Longqing Tablet combined with pharmaceutical chemicals in treatment of type III prostatitis

Objective To evaluate the efficacy and safety of Longqing Tablet combined with pharmaceutical chemicals in the treatment of type III prostatitis, which is chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods Data were electronically searched from the PubMed, Embase, Medline, Web of Science, Cochrane Library, CNKI, Wanfang Data, VIP, and SinoMed to collet randomized controlled trails (RCTs) on Longqing Tablet in the treatment of CP/CPPS. The retrieval time was from database establishment to January 2022. The literatures were screening according to inclusion criteria and exclusion criteria. The Meta-analysis was carried out by Revman 5.4 software. Results A total of eight RCTs were selected, including 1 000 cases (503 cases in the experimental group and 497 cases in the control group). Meta-analysis showed that the NIH-CPSI symptom score (total score) is lower than that of the control group [MD = -2.65, 95%CI (-3.28, -2.03), P<0.000 01]. The pain symptom score is lower than that of the control group [MD = -1.44, 95%CI (-1.95, -0.92), P<0.000 01]. The quality of life score is lower than that of the control group [MD = - 0.50, 95%CI (- 0.93, - 0.06), P=0.03]. There are no significant differences in voiding symptom score between control group and control group [MD=-0.17, 95%CI (-0.85, 0.50), P=0.61], but there are significant differences between experimental group and control group when only use one pharmaceutical chemical in the control group [MD=-0.75,95%CI (-1.43, -0.07), P = 0.03]. The EPS leukocyte count is lower than that of the control group [MD=-4.33,95%CI (-6.59, -2.08), P=0.002]. Finally, there is no significant difference in adverse reaction rate compared with the control group [RR = 1.00, 95%CI (0.46, 2.19), P=0.99]. Conclusion Longqing Tablet can improve the symptoms and reduce leukocyte count of EPS in CP/CPPS patients significantly. Moreover, it do not increase the incidence of adverse reactions significantly.